![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.125 | -2.67% | 4.55 | 4.11 | 4.99 | 4.41 | 4.35 | 4.39 | 482,311 | 16:35:06 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.50 | 9.41M |
Date | Subject | Author | Discuss |
---|---|---|---|
09/11/2020 12:58 | Never mind theres always COPD | ![]() kop202 | |
09/11/2020 12:57 | No need for companies like SNG / AVCT it seemsBack to single digits again? | ![]() scepticalinvestor | |
09/11/2020 12:57 | Such a ridiculous over-reaction by the market | ![]() blakieboy7 | |
09/11/2020 12:54 | 94 people *contracted* it after taking the vaccine - they *are* the 10%... "Phase 3 of Pfizer's trial involved 43,538 participants. They received two doses of either the immunisation or a placebo, with 90% protected from the virus within 28 days of having their jabs. Only 94 people who took part in the trial developed coronavirus and no serious safety concerns were reported, the US pharmaceutical firm said on Mondy."" | ![]() sloppyjoe2 | |
09/11/2020 12:52 | 90% effective on only 94 people. What's not to say it only works on 50% or 60% overall. No breakdown of age or ethnicity etc... This is such a small sample things could change dramatically. Also it's unknown how long the vaccine will be effective for. | firedriver | |
09/11/2020 12:48 | DCBs dont take a day to appear in this market. More like about 5 minutes. | ![]() scrabster1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions